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Hemodialysis prevents liver disease caused by hepatitis C virus: mice have shown that exogenous HGF administration or
Role of hepatocyte growth factor. transgenic HGF expression accelerate liver regeneration
Background. Hemodialysis increases markedly the serum and protect against toxic hepatitis [5–7]. Thus, there is
levels of hepatocyte growth factor (HGF) so that regular dialysis
convincing experimental evidence that HGF is recruitedtreatment (RDT) mimics the regular administration of HGF
after acute liver injury to stimulate liver regenerationas a drug. Therefore, we have studied the effects of dialysis-
and that HGF can protect the liver against toxic insults.associated HGF production on the severity of liver damage
caused by hepatitis C virus (HCV). Clinical studies have shown that serum levels and he-
Methods. Biochemical tests of liver function and liver biopsy patic expression of HGF are increased in patients with
were performed in 10 patients on RDT and in 11 patients without acute and chronic liver disease [8]. However, in patients
renal disease (WRD) converted to anti-HCV serum-positive test
with liver disease, serum HGF seems to correlate withfor the same time (48 6 4 months). The HGF serum concentra-
the degree of liver dysfunction rather than with indicestion was measured by enzyme immunoassay. In patients on
of hepatocyte regeneration [9, 10], and no evidence hasRDT, HGF was measured just before starting a dialysis session
(T0), at 15 and 240 minutes of dialysis (T15 and T240), and 24 been provided that increased HGF production reduces
hours later (T24 hr). liver damage. A direct way to investigate whether HGF
Results. Serum HGF was similar in WRD (average 0.17 affects the course of human disease would be to adminis-
ng/ml) as in RDT at T0 (0.25 ng/ml). In RDT serum HGF ter HGF, but HGF is not yet available for studies inincreased markedly at T15 and T240 (5.51 and 2.67 ng/ml, respec-
humans.tively, P , 0.001 vs. WRD and T0) and was still higher than
Hemodialysis increases serum levels of HGF, and thisbaseline at T24 hr (0.41 ng/ml, P , 0.05). Both grade of necroin-
flammatory activity and stage of fibrosis were significantly phenomenon reflects increased HGF production rather
lower in RDT than in WRD (both, P , 0.001). The number than HGF shedding from low-affinity tissue receptors.
of apoptotic hepatocytes was also significantly reduced in pa- In fact, during dialysis, peripheral blood mononuclear
tients on RDT compared with patients WRD. cells activated by extracorporeal circulation releaseConclusion. These results show that HCV-related liver dis-
HGF, which is rapidly transformed into its active formease is more benign in patients on RDT. The phenomenon
[11]. Thus, regular dialysis treatment (RDT) mimics reg-may depend on the marked and prolonged HGF release caused
by dialysis. ular exogenous HGF administration, and patients receiv-
ing hemodialysis are an excellent model for testing
whether the course of liver disease is modified by in-
creased availability of circulating HGF. The prevalenceHepatocyte growth factor (HGF) was originally iden-
of hepatitis C virus (HCV) infection is very high amongtified in the serum of partially hepatectomized rats [1].
patients on RDT [12]. Therefore, in this study, we testedAnimal studies have shown that both its serum levels
the hypothesis that liver damage caused by HCV infec-and its hepatic expression increase after acute liver injury
tion is less severe in patients on RDT, that is, in patients[2, 3]. In vitro studies have demonstrated that HGF is a
in whom “pharmacological” HGF serum levels challengepotent mitogen for hepatocytes [4], and experiments in
the viral action.
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(WRD)] comparable as to the duration of infection and Apoptosis
HCV genotype so that the effects of dialysis on liver Sections from paraffin-embedded biopsy samples were
disease could be studied in the absence of these con- deparaffinized and digested with proteinase K (20 mg/ml)
founding factors. According to the Wilcoxon rank-sum for 15 minutes at room temperature. One drop of equili-
test, 10 patients in each group were needed to detect a bration 1 3 buffer was applied on the specimen for two
significant difference (at least P , 0.05) in liver biopsy minutes, followed by the application of 10 ml of TdT
indexes with an adequate statistical power (.80%) using enzyme (24 ml TdT enzyme and 76 ml of reaction buffer)
the Mann–Whitney U-test (discussed in the Statistics per cm2. Slides were then incubated for 30 minutes at
section). Patients WRD were enrolled among otherwise 378C in working-strength stop/wash buffer (Apotage;
healthy outpatients undergoing periodical programmed Oncor, Gaithersburg, MD, USA). Then the specimens
anti-HCV testing because of professional or social risk were washed three times with phosphate-buffered saline,
of infection (drug abusers were excluded). Patients on covered with two drops of antidigoxigenum-peroxidase,
RDT were recruited in dialysis centers in which anti- and incubated in a humidifier chamber for 30 minutes
HCV antibody testing was routinely performed every at room temperature. Sections were counterstained with
three months. The examination of patients’ charts al- methyl green for 10 minutes and, after dehydration, were
mounted in Canadian balsam. Negative control for eachlowed identification of 11 patients WRD and 10 patients
slide was obtained by preparing working strength with-on RDT that were recruited, responding to the following
out the addition of TdT enzyme. The apoptosis scorecriteria: (a) Seroconversion had occurred 48 6 4 months
was calculated from the number of positive nuclei perbefore, as documented by two consecutive enzyme-linked
microscopic field (3400). Scores 0, 1, 2, 3, and 4 corre-immunosorbent assays, performed less than four months
sponded to 0, 0 to 25, 26 to 50, 51 to 75, and .75 nuclei,apart and liver enzymes were normal in at least two
respectively.occasions for 12 months before seroconversion; (b) HCV
mRNA was present in serum, and the genotype of virus
Hepatocyte growth factor measurementwas 1b; (c) none received previous treatment for hepati-
Hepatocyte growth factor was measured in serum bytis, and all were candidates to interferon therapy; (d)
a commercial enzyme immunoassay (R&D Systems,serum anti-HIV antibody and HbsAg were negative; and
Minneapolis, MN, USA). The immunoassay uses recom-(e) none were alcohol abusers.
binant human HGF expressed in Sf 21 cells, which pro-
Hepatitis C virus genotyping and hepatitis C virus duce a mixture of monomeric and dimeric HGF, and a
monoclonal antibody specific for HGF that binds withRNA quantitation
no apparent preference to both the monomeric and theHepatitis C virus genotype was determined 7 to 14
dimeric forms.days before performing liver biopsy by a nested reverse
transcription-polymerase chain reaction (RT-PCR), based Biochemical tests of liver function
on core region subtype-specific primers, according to the
In all patients, the following biochemical measure-procedure of Okamoto et al [13] and modified by Silini
ments on serum taken at the time of liver biopsy wereet al [14] for better detection of Italian type 2 isolates.
made: alanine (ALT) and aspartate (AST) aminotrans-Hepatitis C virus RNA was quantitated by branched-
ferase, g-glutamyl transferase (g-GT), cholynesterase,DNA hybridization assay (Quantiplex HCV RNA 2.0
albumin, and bilirubin.Assay; Chiron Corp., Emeryville, CA, USA).
StatisticsLiver biopsy
Analysis of variance and the Newmann–Keuls testAll patients gave written consent to liver biopsy, which
were used to compare the means, and multiple regression
was performed within one month of enrollment in the
and Spearman’s test were used to analyze the correlation
study. Liver samples obtained by Menghini needle were
between the quantity of viral RNA and histologic grad-
fixed in 4% buffered formalin and were routinely stained ing and staging. Two-sided Mann–Whitney U-test was
with hematoxylin and eosin, Masson trichrome, silver used to compare histopathological findings and apoptosis
nitrate, and Perls. Histologic grading and staging were index, and Wilcoxon rank-sum test was used to calculate
quantitatively assessed according to the Histologic Activ- the power of U-test.
ity Index of Knodell et al [15], which was modified by
Ishak et al [16]. Grading produces a numerical index of
RESULTSliver necroinflammation with a maximum score of 18,
whereas staging produces a numerical index of architec- Data of patients and results of liver biochemical tests
tural changes, fibrosis, and cirrhosis with a maximum are shown in Table 1. The age at the time of study,
and therefore at the time of seroconversion, and sexscore of 6.
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Table 1. Liver biochemical tests of hepatitis C virus- (HCV) infected
patients on regular dialysis treatment (RDT) and without renal
disease (WRD)
ALT AST
Age Sex Bilirubin Albumin
years F/M mg/dl g/dlmU/ml
WRD 49.1 3/7 50.0a 58.3b 0.85 4.4
(6.9) (16.7) (27.4) (0.28) (0.4)
RDT 51.6 3/8 15.0 21.2 0.71 4.2
(7.8) (7.1) (10.7) (0.14) (0.4)
Numbers are means and (in parentheses) standard deviations.
a P , 0.0001
b P , 0.0025
Table 2. Hepatitis activity index and serum viral load in HCV-
infected patients on dialysis treatment (RDT)
and without renal disease (WRD)
Patient Biopsy Biopsy Viral load
number grading staging GEq/ml
RDT
1 1 2 200,000
2 3 2 200,000
Fig. 1. Serum levels of hepatocyte growth factor (HGF) in patients3 0 0 200,000
without renal disease (WRD) and in patients on regular dialysis treat-4 2 1 200,000
ment (RDT). Columns are means and bars standard errors. Times T0,5 3 1 200,000
T15, T240, and T24 hr indicate serum sampled just before dialysis at 15 and6 2 1 200,000
240 minutes of dialysis and 24 hours after the end of dialysis, respec-7 2 0 226,000
tively. **P , 0.001 and *P , 0.05 vs. WRD and T0.8 1 1 200,000
9 1 0 200,000
10 2 0 200,000
WRD
1 4 2 4,005,000
was significantly higher in patients WRD than in patients2 8 4 3,373,000
3 3 5 200,000 on RDT (P , 0.05). No correlation was found between
4 2 6 6,993,000 the viral load and histologic grade or stage, neither con-
5 2 6 3,579,000
sidering all patients nor considering separately patients6 4 2 19,770,000
7 5 2 593,000 on RDT and patients WRD.
8 3 1 3,586,000 The apoptosis score was high (3 to 4, median 3) in all
9 6 3 520,000
patients WRD and low (0 to 1, median 0.5) in all patients10 4 2 300,000
11 5 3 2,300,000 on RDT (difference significant at the P , 0.005 level
according to Mann–Whitney test, power 90%). Figure 1Grading is a necroinflammatory index, staging is an index of architectural
changes and fibrosis. shows the effects of hemodialysis on the serum HGF
concentration. HGF serum levels were similar in patients
WRD and patients on RDT just before starting dialysis,
but were strikingly modified by dialysis. HGF serumdistribution were similar in the two groups. ALT and
levels peaked at T15, with a more than 20-fold increase,AST were significantly higher in patients WRD than in
were still 10-fold higher than at T0 at T240 and remainedpatients on RDT.
significantly higher than at baseline for 24 hours afterTable 2 shows the histologic grading and staging scores
the end of the dialysis session.
and the serum viral load in individual patients. Hepatitis
grade ranged from 0 to 3 (median 2) in patients on RDT
DISCUSSIONand from 2 to 8 (median 4) in patients WRD (difference
significant at P , 0.018 level according to Mann–Whitney In this study, we investigated the effects of HCV infec-
U-test; power 88%). Stage of fibrosis ranged from 0 to tion in two groups of patients, one with normal renal
2 (median 1) in patients on RDT and from 1 to 6 (median function and the other with chronic uremia undergoing
2) in patients WRD (difference significant at P , 0.0012 regular hemodialysis treatment. We observed lower bio-
level according to Mann-Whitney U-test; power 89%). chemical indices of hepatic cytolysis and milder histo-
The viral load was about 200,000 GEq/ml in all patients logic lesions, both as inflammatory activity and fibrosis
on RDT, whereas it ranged from 300,000 to 19,770,000 in patients receiving hemodialysis. Previous studies have
shown that serum aminotransferase levels are usuallyGEq/ml in patients WRD. Thus, the average viral load
Rampino et al: HGF protects HD patients from HCV 2289
normal or only slightly elevated in hemodialysis patients by leukocytes activated in the extracorporeal circulation
[34]. In HCV-infected patients, serum levels attainedwho are infected with HCV [17, 18], suggesting that
uremia predisposes to a chronic viral “carrier” status during hemodialysis are 10 to 20 times higher than those
observed in patients with chronic hepatitis and cirrhosiswith little inflammatory activity in the liver [19]. How-
ever, liver enzymes do not reflect the extent of liver and are comparable to levels observed in patients with
massive acute parenchymal damage, such as renal tubu-damage [20, 21] so that liver biopsy is necessary to under-
stand HCV-related liver disease. Until now, the only lonecrosis [35] and fulminant hepatic failure [6, 8], which
are the conditions that represent the maximum knownattempt to compare liver biopsy findings in nonuremic
and dialysis patients infected with HCV was performed stimulus to HGF release.
Hepatocyte growth factor is not yet available for injec-by Akpolat et al [22]. Their findings suggested that hepa-
titis is milder in hemodialysis patients, but they admitted tion in humans, but recombinant HGF has been injected
in mice in doses that were able to prevent toxic hepatitisthat no definite conclusion could be drawn because of the
limited number of patients studied. In addition, they did [5] and renal tubulonecrosis [36]. Although in these ex-
perimental studies the pharmacokinetics of HGF wasnot define the duration of infection nor the viral genotype,
that is, two main determinants of virus C-related liver not performed, the HGF serum concentration was 5 ng/ml
at 30 minutes and 0.5 ng/ml at one hour after intravenousdisease [23, 24]. Therefore, our study gives the first con-
trolled evidence that hemodialysis modifies the course administration, which are the levels of the same magni-
tude as those observed during hemodialysis. Therefore,of HCV-related liver disease. In fact, in comparing pa-
tients on RDT with controls, we excluded biases caused our patients on RDT may be viewed as if they received
pharmacological doses of HGF three times weekly andby the duration of disease, age at infection, virus geno-
type, treatment with interferon, or association with other for an approximate period of four years. We suggest that
the regular and prolonged production of HGF causedcauses of liver damage. All patients had circulating virus
RNA, although the viral load was lower in patients on by hemodialysis, raising serum HGF to pharmacological
levels, accounts for the protective effect of hemodialysisRDT, in agreement with previous findings [25]. In patients
on RDT, the viral load may be reduced by extracorporeal on liver damage caused by HCV. Admittedly, we cannot
state beyond any doubt that a causal relationship existsultrafiltration [26], but we could not demonstrate any
change in viral RNA at the end of dialysis session (data between high HGF levels and less liver damage in patients
infected by HCV. On the other hand, studies demonstrat-not shown). Serum RNA levels depend on the viral repli-
cation rate, and several studies have investigated the rela- ing such a relationship on a more sound basis would re-
quire HGF for human use or a model of viral hepatitis intionship of RNA titer to the extent of liver disease, yield-
ing conflicting results. Some authors concluded that the animals, both not currently available. However, in agree-
ment with our hypothesis, the administration of HGFviral load is unrelated to the histologic diagnosis [27, 28],
whereas others found higher RNA titers in patients with suppressed the onset of liver fibrosis/cirrhosis in several
rat models of nonviral liver disease [37, 38]. In addition,more active or more advanced disease [29, 30]. These
discrepancies probably reflect the variety of determi- repeated transfections of the human HGF gene, inducing
high endogenous HGF plasma levels, afforded completenants that can influence viremia and liver damage. These
variables include viral replication in peripheral blood protection in a rat model of liver cirrhosis [39].
Understanding the mechanisms by which HGF attenu-mononuclear cells [31], strength of cytotoxic T lympho-
cyte response [32], viral genotype, and mode and dura- ates the damage caused by HCV to the liver was not
the aim of our study. HGF is a potent stimulator oftion of infection [28]. In our patients, there was no corre-
lation between serum viral load and the histologic indices, hepatocyte proliferation, and part of its protective effect
may result from accelerated liver repair. Another protec-confirming that viral RNA levels cannot predict the
grade and stage of liver damage. tive mechanism may consist of the suppression of HCV-
induced apoptosis. In fact, HGF rescues epithelial cells,We previously showed that hemodialysis is a potent
stimulus to HGF production, that the stimulus is inde- including hepatocytes, from apoptosis caused by differ-
ent mechanisms [40–43], and abrogates Fas-induced ful-pendent of heparin use [33], and that HGF released
during dialysis is rapidly transformed into its biologically minant hepatic failure [44]. In addition, Fas-mediated
apoptosis plays an important role in cell injury causedactive form [11]. In this study, we demonstrate that HGF
serum levels increase strikingly during dialysis also in by HCV infection [45, 46], and the protective effect of
HGF in a rat model of liver cirrhosis was associatedHCV-infected patients and demonstrate that in these
patients, the rise in HGF is long lasting; that is, it is with inhibition of hepatocyte apoptosis [38]. Indeed, we
evaluated apoptosis in liver biopsies and found a muchmaintained for 24 hours after the end of treatment. Pe-
ripheral blood mononuclear cells and mesenchymal cells lower number of apoptotic nuclei in patients on RDT.
The results of our study provide a basis for the possiblein solid tissues are the source of HGF released during
dialysis; these cells are stimulated by cytokines produced future therapeutic use of HGF in chronic hepatitis C.
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